Navigation Links
Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Date:10/27/2008

.com/investors.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's future regulatory filings and the timing and outcome thereof and the company's expected financial and operating results. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, the risk that significant improvement in RA signs and symptoms will not be observed after further re-treatment with TRU-015, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, the risk that the Company does not achieve the financial and operating results it expects, and such other risks as identified in the company's quarterly report on Form 10-Q for the period ended June 30, 2008, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate website at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact:

Jim DeNike

Senior Director, Corporate Communications

Trubion Pharmaceuticals Inc.

(206) 838-0500

jdenik
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
2. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
3. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
4. Trubion Announces Presentations at April/May Investor Conferences
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
7. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
10. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
11. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... BRYAN, Texas and COLLEGE STATION, Texas ... hotel theatlashotel.com will be a 177-key, 4-star ... Traditions in Bryan , Texas.  ... As the first hotel within ... will include 177 rooms, a mixture of standard rooms and suites, ...
(Date:7/26/2014)... Albany, NY (PRWEB) July 26, 2014 ... 2020 provides key market data on the Canada ... in millions of US dollars, volume (in units) ... segments - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy ... Browse Full Report at http://www.marketresearchreports.biz/analysis/213254 . , ...
(Date:7/25/2014)... in each person,s digestive tract. Scientists believe that some ... harmful infections, but their role in human health is ... the role of these bacteria, a team of researchers ... fluctuations in the bacterial populations of two research subjects ... July 25 issue of the journal Genome Biology ...
(Date:7/25/2014)... According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... at USD 161,056.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... is witnessing a significant growth due to the increasing ...
Breaking Biology Technology:Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
... , SAN MARINO, Calif., Aug. 26 ... drug compounds for HIV/AIDS, autoimmune diseases, and cancer, is issuing this ... collegestock.com on August 25 and August 26, and an article published ... Something About Viral Genetics, Inc. (VRAL)," on August 25. , ...
... , KENILWORTH, N.J., Aug. 26 Schering-Plough ... European Medicines Agency (EMEA) has validated (accepted for review) the ... mometasone furoate and formoterol fumarate for the maintenance treatment of ... The company also announced today that the EMEA has validated ...
... , , DURHAM, N.C., Aug. ... that the company will present at investor conferences in New York ... , Kirk Harrington, senior vice president, Warfighter Division and ... Investment Conference in New York on September 9, 2009 at 2:00 ...
Cached Biology Technology:Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases 2Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases 3Schering-Plough Announces Two European Filings 2Schering-Plough Announces Two European Filings 3Schering-Plough Announces Two European Filings 4Schering-Plough Announces Two European Filings 5Schering-Plough Announces Two European Filings 6Schering-Plough Announces Two European Filings 7Schering-Plough Announces Two European Filings 8Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich 2
(Date:7/27/2014)... new in vitro study has revealed that nicotine and ... damage caused by a certain carcinogen in smoke. , ... curing of tobacco leaves and ultimately ends up in ... the lung and liver, where it is activated by ... research in mice has revealed that nicotine can partially ...
(Date:7/27/2014)... date, researchers from the U.K. provide national, regional, and ... (HCV). Findings published in Hepatology, a journal of the ... that genotype 1 is the most prevalent worldwide, with ... in East Asia. Genotype 3, at just over 54 ... genotypes 2, 4, 6, and 5. , Despite ...
(Date:7/27/2014)... can evade treatment by acquiring mutations in the genes ... were once thought to be the only way for ... shown that microorganisms can use a temporary silencing of ... the benefits of drug resistance without the commitment. , ... called Mucor circinelloides, it is likely to be employed ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Hepatitis C virus genotype 1 is most prevalent worldwide 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3
... new mechanism of infection for the most fatal bee ... which can kill entire colonies of bees. Every year, ... beekeepers all over the world. The only control measure ... of infection (pathogenic mechanism) was originally thought to be ...
... 1 Stinger Systems, Inc. (OTC,Bulletin Board: STIY), ... had reached a settlement agreement with the Securities ... settled the matter without admitting or,denying wrongdoing and ... Systems, Inc. also said that no fines or ...
... of physical oceanographers including a researcher from Scripps Institution ... oxygen-poor regions of tropical oceans are expanding as the ... and other marine organisms can live or enter in ... by Lothar Stramma from the Leibniz Institute of Marine ...
Cached Biology News:Bees disease -- 1 step closer to finding a cure 2Oxygen depletion: A new form of ocean habitat loss 2
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
Biology Products: